

## MU Biosafety Questionnaire

Research core facilities are multi-user laboratories that offer services to investigators both on and off campus. Researchers bring samples derived from a variety of sources for analysis at the EMC, and these samples can potentially harbor pathogens capable of transmitting disease. Since the safety of facility personnel and users is of utmost important, the EMC requests detailed information about the source of the sample and method of preparation. Information provided by the principal investigator on this form will be used to assess the risk level to personnel and users so the appropriate safety measures can be followed and the risk of exposure to biohazardous materials minimized.

Please fill out this questionnaire and include as many details as possible. Both the investigator analyzing the samples and the principal investigator should sign the form, and the completed form should be submitted to EMC as soon as possible before the planned experiment. Once the form is approved by EMC staff, the experiment will be scheduled.

**Date:**

**Project Title:**

**Principal Investigator:**

Name:

Phone Number:

E-mail:

**Scientist analyzing samples:**

Name:

Phone Number:

E-mail:



**Project start date and end date:**

Start: mm/dd/year End: mm/dd/year

**Does this project have a current Institutional Biosafety Committee(IBC) approval?**

**Yes.** Attach a copy of IBC approval Letter or IBC protocol number

**No.**

If no, the samples cannot be run until the IBC committee has approved the study.

Questions? Contact the Environmental Health & Safety Office at (573) 882-7018

**Exempt.** (No known infectious agents or exempt from IBC approval)

**Briefly summarize the project.** In one paragraph or less, provide general information about the project and specific information about the source of cells and the method of sample preparation.

**List the origin (tissue) and species of the sample (e.g., mouse spleen cells). For established cell lines, describe the species/tissue of the cell line and the source where it was obtained (another laboratory, commercial source).**

Human  Primate  Mouse  Rat  Bacteria

Other \_\_\_\_\_

Primary cells (taken from animals but not cultured *in vitro*)

List species and tissue: \_\_\_\_\_

Cultured primary cells (primary cells that have been cultured in vitro for any amount of time)

List species and tissue \_\_\_\_\_

Established cell lines

Name of cell line, species, and tissue \_\_\_\_\_

Source where cell line obtained from \_\_\_\_\_

Has the cell line been transformed by or carry any known viral pathogens?

Yes  No

If yes, provide details: \_\_\_\_\_

**Will the samples be treated with any pharmacological agents?**

Yes  No

If yes, list pharmacological agents:

---

---

**Do the samples contain any known infectious agents or other known human pathogens?**

Yes  No

If yes, list infectious agents or known human pathogens:

---

---

**Note:** The infectious agents/known pathogens must be listed on your IBC approval letter with the method of containment indicated.

**If using samples from a human donor, has the donor or sample been screened for blood-borne pathogens (e.g. HIV, HBV, HCV, etc)?**

Yes  No  Not Applicable

**Have the cells been tested for viral infection (HIV, HBV, SIV, etc.) and/or mycoplasma infection?**

Yes  No

If yes to either question, provide a copy of the most recent test results.

---

---

---

---



**Has the infectious agent been inactivated or rendered non-infectious?**

Yes  No  Not Applicable

If yes, describe method of inactivation. Provide proof of inactivation, if applicable.

---

---

---

---

**Will the samples be fixed prior to use on the flow cytometry analyzers or sorter?**

Yes  No

If yes, describe the fixation protocol in detail (e.g., list concentration and exposure time).

---

---

**Note: All human samples MUST be fixed before high pressure or plunge freezing**

**Have the cells been transformed or genetically engineered using a viral system (e.g., EBV, HTLV-1, etc.) or recombinant DNA?**

Yes  No

If yes, has a gene therapy virus been used?

Yes  No

Plasmid or viral vector: \_\_\_\_\_ (e.g., LentimMax or other)

Details about insert: \_\_\_\_\_

Details about enhancers/promoters/other viral components: \_\_\_\_\_

Is the insert an oncogene:  Yes  No

If yes, provide details of insert: \_\_\_\_\_

If virus, is it replication incompetent:  Yes  No

Capacity of virus to infect human cells: \_\_\_\_\_

Are transduced cells passaged at least 3 times prior to analysis:  Yes  No

IBC protocol number: \_\_\_\_\_

**Will the cells be derived from transgenic plants?**

Yes  No

Plasmid backbone or viral vector: \_\_\_\_\_

Details about insert (gene of interest): \_\_\_\_\_

Details about enhancers/promoters/other viral components: \_\_\_\_\_

Is the insert an oncogene:  Yes  No

If yes, provide details of insert: \_\_\_\_\_

IBC protocol number: \_\_\_\_\_



# Electron Microscopy Core

University of Missouri

W117 Veterinary Medicine  
1600 E. Rollins St.  
Columbia, Missouri 65211  
Telephone: (573) 882-8304  
<http://emc.missouri.edu/>

Entering your name indicates you have read above questions carefully and certify the information provided to be correct

\_\_\_\_\_  
Signature, Scientist

\_\_\_\_\_  
Date (mm/dd/year)

**FOR EMC USE ONLY**

**COMMENTS:**

**BIOSAFETY LEVEL:** \_\_\_\_\_

**APPROVED:** Yes \_\_\_\_\_ No \_\_\_\_\_ **DATE:** \_\_\_\_\_

**APPROVED BY:** \_\_\_\_\_